JP7657287B2 - 組合せブタワクチン - Google Patents

組合せブタワクチン Download PDF

Info

Publication number
JP7657287B2
JP7657287B2 JP2023504581A JP2023504581A JP7657287B2 JP 7657287 B2 JP7657287 B2 JP 7657287B2 JP 2023504581 A JP2023504581 A JP 2023504581A JP 2023504581 A JP2023504581 A JP 2023504581A JP 7657287 B2 JP7657287 B2 JP 7657287B2
Authority
JP
Japan
Prior art keywords
vaccine
pcv
antigen
animal
lawsonia intracellularis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023504581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535066A (ja
Inventor
エドガー ディアス
グレッグ スチュアート クライン
ジェレミー クロール
フェルナンド ロペス レイヴァス レイテ
マイケル ビー ルーフ
マイク アラン ステイレン
Original Assignee
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド filed Critical ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド
Publication of JP2023535066A publication Critical patent/JP2023535066A/ja
Priority to JP2024193753A priority Critical patent/JP2025026461A/ja
Application granted granted Critical
Publication of JP7657287B2 publication Critical patent/JP7657287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023504581A 2020-07-24 2021-07-22 組合せブタワクチン Active JP7657287B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024193753A JP2025026461A (ja) 2020-07-24 2024-11-05 組合せブタワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063055947P 2020-07-24 2020-07-24
US63/055,947 2020-07-24
EP20196349.3 2020-09-16
EP20196349 2020-09-16
PCT/US2021/042778 WO2022020593A2 (en) 2020-07-24 2021-07-22 Combination porcine vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193753A Division JP2025026461A (ja) 2020-07-24 2024-11-05 組合せブタワクチン

Publications (2)

Publication Number Publication Date
JP2023535066A JP2023535066A (ja) 2023-08-15
JP7657287B2 true JP7657287B2 (ja) 2025-04-04

Family

ID=77274829

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023504581A Active JP7657287B2 (ja) 2020-07-24 2021-07-22 組合せブタワクチン
JP2024193753A Pending JP2025026461A (ja) 2020-07-24 2024-11-05 組合せブタワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024193753A Pending JP2025026461A (ja) 2020-07-24 2024-11-05 組合せブタワクチン

Country Status (12)

Country Link
US (1) US20230241198A1 (https=)
EP (1) EP4185321A2 (https=)
JP (2) JP7657287B2 (https=)
KR (1) KR20230044474A (https=)
CN (1) CN116157147A (https=)
AU (1) AU2021311726A1 (https=)
BR (1) BR112023001324A2 (https=)
CA (1) CA3185751A1 (https=)
CL (1) CL2023000118A1 (https=)
CO (1) CO2023000299A2 (https=)
MX (1) MX2023001024A (https=)
WO (1) WO2022020593A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036260A (zh) * 2022-12-30 2023-05-02 哈药集团生物疫苗有限公司 猪圆环病毒、猪肺炎支原体、猪塞内卡病毒三联灭活疫苗及其制备方法和应用
WO2024260953A1 (en) * 2023-06-23 2024-12-26 Intervet International B.V. A method of culturing lawsonia intracellularis bacteria
CN118477172A (zh) * 2024-01-09 2024-08-13 浙江鼎持生物制品有限公司 一种猪三联灭活疫苗及其制备方法
CN118894910B (zh) * 2024-07-24 2026-03-06 华南农业大学 一种PRRSV-GP3-GP5-M+PCV2-TBCap重组蛋白、疫苗及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545618A (ja) 2005-03-14 2008-12-18 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ローソニア・イントラセルラリスを含む免疫原性組成物
JP2016531859A (ja) 2013-09-27 2016-10-13 インターベット インターナショナル ベー． フェー． 室温安定であるワクチンの乾燥製剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
JP3128133B2 (ja) 1991-06-06 2001-01-29 スティッチティング セントラール ディールゲネースクンディグ インスティトゥート 豚の奇病の原因体であるレリスタドエイジェント、それを含むワクチン組成物、豚の奇病の診断キット及び診断方法
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
DK0601062T4 (da) 1991-08-26 2001-03-14 Univ Minnesota SIRS-vaccine og diagnosefremgangsmåde
AU2696792A (en) 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
DE69522984T2 (de) 1994-04-11 2002-04-25 Akzo Nobel Nv Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Schweins
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
EP0732340B1 (en) 1995-03-14 2004-06-09 Akzo Nobel N.V. Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
EP0835930B1 (en) 1996-10-09 2001-01-31 Akzo Nobel N.V. European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
DE602004023094D1 (de) 2003-07-25 2009-10-22 Boehringer Ingelheim Vetmed Lawsonia intracellularis europäischen ursprungs unür
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
DK3766518T3 (da) 2005-12-29 2026-04-13 Boehringer Ingelheim Animal Health Usa Inc Immunogen pcv2-sammensætning til mindskelse af kliniske symptomer hos grise
EP3868400A1 (en) * 2005-12-29 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
PT2094872T (pt) 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Tratamento de porcos seropositivos para o anticorpo anti-pcv2 com antigénio de pcv2
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
PH12013501708B1 (en) 2011-02-17 2018-08-03 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of prrsv
HRP20151031T1 (hr) 2011-02-17 2015-11-06 Boehringer Ingelheim Vetmedica Gmbh Novi europski soj prrsv
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545618A (ja) 2005-03-14 2008-12-18 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ローソニア・イントラセルラリスを含む免疫原性組成物
JP2016531859A (ja) 2013-09-27 2016-10-13 インターベット インターナショナル ベー． フェー． 室温安定であるワクチンの乾燥製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Schweizer Archiv fur Tierheikunde ，2012年，Vol. 154, No. 10, pp. 445-450

Also Published As

Publication number Publication date
AU2021311726A1 (en) 2023-02-09
CA3185751A1 (en) 2022-01-27
WO2022020593A3 (en) 2022-02-24
KR20230044474A (ko) 2023-04-04
MX2023001024A (es) 2023-02-15
CO2023000299A2 (es) 2023-01-26
CN116157147A (zh) 2023-05-23
BR112023001324A2 (pt) 2023-02-14
WO2022020593A2 (en) 2022-01-27
CL2023000118A1 (es) 2023-09-08
EP4185321A2 (en) 2023-05-31
US20230241198A1 (en) 2023-08-03
JP2023535066A (ja) 2023-08-15
JP2025026461A (ja) 2025-02-21

Similar Documents

Publication Publication Date Title
US10780156B2 (en) Treatment of pigs with PCV2 antigen
JP7657287B2 (ja) 組合せブタワクチン
CN102698263B (zh) 多价pcv2免疫原性组合物和制备此类组合物的方法
JP5701191B2 (ja) Ｐｃｖ２免疫原性組成物および組成物を製造する方法
RU2522849C2 (ru) Лечение prdc у молодых свиней
AU2017353380B2 (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
US12433942B2 (en) Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
CA2712006A1 (en) Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
CN102660578B (zh) Pcv2免疫原性组合物和产生这种组合物的方法
EA051536B1 (ru) Комбинированная свиная вакцина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250325

R150 Certificate of patent or registration of utility model

Ref document number: 7657287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150